Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy

Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy

Abstract Objectives Central nervous system (CNS) metastases including brain metastases (BM) and leptomeningeal metastases (LM) are frequent in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), and are correlated with poor outcomes. In this study, we evaluated the ef...

Full description

Bibliographic Details
Main Authors: Ziyi Xu, Xuezhi Hao, Qi Wang, Ke Yang, Junling Li, Puyuan Xing
Format: Article
Language:English
Published: BMC 2023-03-01
Series:BMC Cancer
Subjects:
EGFR-mutated NSCLC
BM/LM
Furmonertinib
Anti-angiogenic agent
Salvage therapy
Online Access:https://doi.org/10.1186/s12885-023-10676-x

Similar Items

Similar Items